BioNTech faces its biggest post pandemic crisis BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
Original (en)
BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
Counterfeit Keytruda (pembrolizumab), an immunotherapy cancer treatment, has infiltrated pharmaceutical supply chains and reached patients and hospitals. The fake medications pose potentially fatal consequences for cancer patients depending on authentic treatment, indicating significant health system vulnerability to pharmaceutical fraud.
The World Food Programme reports a significant funding shortfall that could result in cuts to humanitarian aid in Sudan within weeks as famine conditions worsen. More families across Sudan are being pushed toward famine as international support mechanisms face resource constraints.
UNICEF warns that children in Darfur are facing a new humanitarian catastrophe, two decades after the initial crisis. The alert highlights ongoing vulnerability of the child population and suggests critical gaps in humanitarian response in the region.
60291a0a…openwatch.io →